Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05099107
Other study ID # COMPIS
Secondary ID 2019-001147-51
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date October 25, 2021
Est. completion date December 31, 2025

Study information

Verified date May 2023
Source Vastra Gotaland Region
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Congenital myopathies (CM) is a large group of muscle disorders, presenting with hypotonia and non-progressive generalised muscle weakness, which can lead to motor developmental delay.More than 20 genes can cause CM and currently there is no curative treatment for this disorder. Case reports and a smaller study have previous reported that oral salbutamol has benefited subjects with different types of congenital myopathies by increasing their muscle strength.The exact effect of salbutamol in muscle cells isn't exactly known but it has been hypothesized to have an anabolic effect by triggering different pathways inside the muscle cells which increase cell proliferation, decrease apoptosis, decreases proteolysis and increases protein synthesis. The aim of our study is evaluate if daily oral salbutamol can increase the muscle function and muscle strength in these patients after 6 months on treatment, compared to no treatment.


Description:

We hypothesise that congenital myopathy subjects treated with daily oral salbutamol will increase in their motor function measure 32 test (MFM32) with at least 3 points after 6 months of treatment as compared to no treatment. We have calculated that a sample size of 20 subjects is needed for this study. Congenital myopathy subjects will be recruited from the whole of Sweden and the study will be performed at the Sahlgrenska university hospital in Gothenburg Sweden. The subjects must have clinical symptoms consistent with congenital myopathy and have a verified mutation in a gene known to cause congenital myopathy. After a screening period of 6 months the eligible subjects will be randomised into two groups, group A and group B . During period 1, group A will receive oral salbutamol 3 times daily and the group B will have no treatment.They will be evaluated after 6 months. Then after a washout period of 1 month, Period 2 will begin where the groups will cross-over, i.e group A will have no treatment and group B will receive oral salbutamol 3 times daily. In total each subject will be evaluated 5 times during 19 months with the same battery of muscle function and strength tests performed each time.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 20
Est. completion date December 31, 2025
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender All
Age group 6 Years to 30 Years
Eligibility Inclusion Criteria: - Signed informed consent from legal guardians/patients and patient (where applicable) - Subject must have a confirmed congenital myopathy(CM) diagnosis defined as: - Clinical symptoms consistent with CM with pathohistological findings on muscle biopsy and known genetic mutation consistent with CM OR - Clinical symptoms consistent with CM with unspecific pathohistological changes but known genetic mutation consistent with CM - Stabile motor function tests over at least 6 months (between baseline and screening) - If on other medications- stabile dose for at least 6 months prior to start - At least 1 point on Motor function measure 32 test is (MFM32) at screening visit. >5- <31 years of age (from 6 years to 30 years of age) - Women of fertile age must be on oral contraceptives - Underwent cardiac evaluation with ECG and 2D echocardiography in the last 2 years and has no signs or symptoms of cardiac abnormality. Exclusion Criteria: - Subject with clinical symptoms consistent with CM but has no confirmed genetic mutation and only unspecific changes on muscle biopsy that are not confined to just CM but can be seen in other disorders. - Younger than 6 years of age and older than 30 years - Subject receives 94 or more points on MFM32 test at screening visit. - Subject doesn't not speak Swedish and a translator is needed in order to perform the tests included in the study. - Subject smokes more than 10 cigarettes a day or has smoked more than 10 cigarettes in the last year - Subject has tracheostomy - Subject receives no points on motor function measure test at screening - Subject has other concomitant chronic diagnosis that can affect the patients motor function, in the opinion of the investigator - Subject is currently or has been on oral corticosteroids in the last 6 months - Subject has arrhythmia as seen on electrocardiogram(ECG), confirmed by cardiologist - Subject has cardiomyopathy as seen on ultrasound, confirmed by cardiologist - Subject has severe behavioural and/ cognitive problems that preclude participation in the study, in the opinion of the investigator - Subject is allergic or hypersensitive to study drug or any of its constituents - Subject has previous or ongoing medical condition, medical history, physical findings or laboratory abnormalities that could affect safety, make it unlikely that treatment and follow- up will be correctly completed or impair the assessment of study results, in the opinion of the Investigator; - Subject is currently taking any other investigational drug or has taken any other investigational drug within 3 months prior to the first dose of study medication - Subject is planning on participating in any other study during the duration of this study. - Female subjects of fertile age that are or are planning to become pregnant during the study. - Female subjects that have given birth up to 1 year prior to baseline visit and/or are nursing up to 1 month prior of baseline visit - Subject has a fracture in the last 6 months before the study start or has acquired a fracture during the study.

Study Design


Intervention

Drug:
Salbutamol (as Salbutamol Sulfate) 2 Mg Oral Tablet
taken 3 times daily for 6 months
Salbutamol Only Product in Oral Dose Form
taken 3 times daily for 6 months

Locations

Country Name City State
Sweden Sahlgrenska university hospital Gothenburg Västra Götaland

Sponsors (1)

Lead Sponsor Collaborator
Vastra Gotaland Region

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Motor function measure test 32 (MFM32) score presented as a total score from 0 to 96 points, the higher the score the better motor function 19 months
Secondary timed function tests seconds 5 evaluations in 19 months
Secondary 6 minute walk test meters/minute for speed calculation, as well as total distance walked. 5 evaluations in 19 months
Secondary hand grip test measured in pounds 5 evaluations in 19 months
Secondary 5 consecutive 9 hole PEG test measured in seconds 5 evaluations in 19 months
Secondary muscle myometry test using a hand held myometer measured in newtons 5 evaluations in 19 months
Secondary Activity limitation ACTIVLIM- quality of life questionnaire measured as total score, 0-32 max points, the higher the score the less the limitation in activities 5 evaluations in 19 months
See also
  Status Clinical Trial Phase
Withdrawn NCT04976972 - A Comparison of Patients Receiving a Total Knee Replacement With Robotic Assistance or With Conventional Instrumentation N/A
Recruiting NCT05546541 - Epidemiology and Nutrition
Completed NCT05071469 - Comparison of Two Different Treatment Methods N/A
Completed NCT05041400 - Distribution of Knee Isokinetic Angle-specific Moments and Ratios N/A
Not yet recruiting NCT06216028 - Bone Marrow Aspirate Concentrate (BMAC) Treatment for Knee Osteoarthritis Phase 3
Not yet recruiting NCT04932993 - Writing Down Goals N/A
Completed NCT02944448 - A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee Phase 2
Completed NCT02257489 - Phase 1 Study of ACE-083 in Healthy Subjects Phase 1
Completed NCT02256098 - RSA RCT: ATTUNEā„¢ TKA Versus PFC Sigma TKA N/A
Completed NCT02269254 - Persona Versus NexGen N/A
Completed NCT01979731 - Effects Job Rotation in the Prevention of Work Related Musculoskeletal Disorders N/A
Active, not recruiting NCT01440153 - Additional Exercise Program in Professional Dancers N/A
Completed NCT00968266 - Improving Beliefs About Medication in Patients With Rheumatoid Arthritis N/A
Completed NCT05222126 - Efficacy of Ultrasound-Guided Hydrodissection in Carpal Tunnel Syndrome N/A
Completed NCT05062694 - Physical Therapy Management Of The Patient With Central Sensitization
Recruiting NCT05564182 - High Intensity Laser Therapy in the Treatment of Hemiplegic Shoulder Pain N/A
Completed NCT04009369 - Impacts of Physiotherapy Services in a Quebec Emergency Department N/A
Completed NCT05561452 - The Efficacy of PRP Injection in the Treatment of Rotator Cuff Syndrome N/A
Recruiting NCT05432609 - Standardization and Reproducibility Regarding Scanning Procedures and Measurements of Weight-bearing Cone Beam CT in the Lower Extremity
Completed NCT04959162 - The Effect of Theoretical Knowledge on Resident's Practical Performance in Musculoskeletal Ultrasound N/A